Essel Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.88 M
- Company Age 33 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.28 Cr
- Revenue Growth -13.85%
- Profit Growth -19.30%
- Ebitda 7.40%
- Net Worth 4.93%
- Total Assets 12.33%
About Essel Pharmaceuticals
Essel Pharmaceuticals Private Limited (EPPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 04 November 1991 and has a history of 33 years and two months. Its registered office is in Kanpur Nagar, Uttar Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.88 M.
The company currently has active open charges totaling ₹2.28 Cr.
Indu Saraf, Mitesh Saraf, Khushboo Saraf, and Three other members serve as directors at the Company.
Company Details
-
Location
Kanpur Nagar, Uttar Pradesh, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24239UP1991PTC013679
-
Company No.
013679
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
04 Nov 1991
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Kanpur
Industry
Who are the key members and board of directors at Essel Pharmaceuticals?
Board Members (6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Parmod Lohia
|
Director | 04-Nov-1991 | Current |
|
Mitesh Saraf
|
Director | 30-Mar-2015 | Current |
|
Indu Saraf
|
Director | 04-Nov-1991 | Current |
|
Khushboo Saraf
|
Director | 30-Mar-2015 | Current |
|
Ramesh Saraf
|
Director | 04-Nov-1991 | Current |
|
Manju Lohia
|
Director | 04-Nov-1991 | Current |
Financial Performance of Essel Pharmaceuticals.
Essel Pharmaceuticals Private Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 13.85% decrease. The company also saw a substantial fall in profitability, with a 19.3% decrease in profit. The company's net worth moved up by a moderate rise of 4.93%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Essel Pharmaceuticals?
In 2021, Essel Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹22.80 M
₹0
Charges Breakdown by Lending Institutions
- Others : 2.18 Cr
- Hdfc Bank Limited : 0.10 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 28 Aug 2024 | Others | ₹1.50 M | Open |
| 09 Jul 2024 | Others | ₹2.03 Cr | Open |
| 21 Jan 2022 | Hdfc Bank Limited | ₹0.50 M | Open |
| 02 Jul 2021 | Hdfc Bank Limited | ₹0.50 M | Open |
How Many Employees Work at Essel Pharmaceuticals?
Unlock and access historical data on people associated with Essel Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Essel Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Essel Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
